PLAINSBORO, N.J. – Novo Nordisk today announced a new multi-month subscription program for Wegovy (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.
"The new Wegovy subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. "By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes."
Novo Nordisk Subscription program details
This first and only subscription program for FDA-approved Wegovy will be available beginning March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and others to follow soon. Patients can save up to $600/year on the Wegovy pill and up to $1,200/year on the Wegovy injection with a 12-month subscription and should contact their telehealth providers directly for eligibility and enrollment details.
Eligible self-pay patients can choose 3-, 6- or 12-month subscriptions, with longer subscription periods offering lower monthly pricing:
Wegovy pen (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)*
- 3-month subscription: $329/month, a savings of $240 per year
- 6-month subscription: $299/month, a savings of $600 per year
- 12‑month subscription: $249/month, a savings of $1,200 per year
Wegovy pill (9 mg and 25 mg doses)**
- 3-month subscription: $289/month, a savings of $120 per year
- 6-month subscription: $269/month, a savings of $360 per year
- 12‑month subscription: $249/month, a savings of $600 per year
*Wegovy HD (semaglutide) injection 7.2 mg will be added at a later date.
**Self-pay patients pay $149 for each month of 1.5 mg and 4 mg. 4 mg offer available until August 31, 2026, then $199 per month for 4 mg.
Limited-time offers are separate and distinct and not included in monthly subscriptions. Patients should contact their telehealth provider directly for complete program terms, as these vary by platform.
Obesity is a chronic disease that requires ongoing management under the care of a healthcare professional. The subscription model is designed to help support people living with obesity by providing greater cost predictability and encouraging treatment consistency so that people focus on their long-term weight management goals in partnership with their healthcare teams.
In addition to working with select telehealth providers, Wegovy is available through a range of additional access points, including more than 70,000 US pharmacies and NovoCarePharmacy. Those with commercial insurance coverage can access Wegovy for as little as $25 per month through existing savings programs.
